Characterization of V36C, a novel amino acid substitution conferring Hepatitis C Virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease

16Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We characterized a novel substitution conferring moderate resistance to telaprevir, a peptidomimetic inhibitor of hepatitis C virus protease. V36C conferred a 4.0-fold increase in the telaprevir 50% inhibitory concentration in an enzyme assay and a 9.5-fold increase in the replicon model. The replication capacity of a replicon harboring V36C was close to that of the wild-type protease. This case emphasizes the complexity of hepatitis C virus resistance to protease inhibitors. Copyright © 2010, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Barbotte, L., Ahmed-Belkacem, A., Chevaliez, S., Soulier, A., Hézode, C., Wajcman, H., … Pawlotsky, J. M. (2010). Characterization of V36C, a novel amino acid substitution conferring Hepatitis C Virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease. Antimicrobial Agents and Chemotherapy, 54(6), 2681–2683. https://doi.org/10.1128/AAC.01796-09

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free